Review
Endocrinology & Metabolism
L. dos Santos Ferreira, L. G. Abreu, C. B. Calderipe, M. D. Martins, L. F. Schuch, A. C. U. Vasconcelos
Summary: The study aimed to integrate data on the use of TPTD for MRONJ cases, finding that TPTD in combination with another therapy, especially antibiotic therapy, can be considered an effective protocol for MRONJ.
OSTEOPOROSIS INTERNATIONAL
(2021)
Review
Oncology
Akanksha Srivastava, Graciela M. Nogueras Gonzalez, Yimin Geng, Alexander M. Won, Maria E. Cabanillas, Aung Naing, Jeffrey N. Myers, Yisheng Li, Mark S. Chambers
Summary: This study investigated the prevalence of MRONJ in patients receiving two or more sequential ARDs compared to a single antiresorptive drug. The results showed an increased prevalence of MRONJ associated with sequential ARD therapy, such as pamidronate-zoledronate and bisphosphonate-denosumab, when compared to single ARD therapy.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Endocrinology & Metabolism
T. Hasegawa, N. Ueda, SI. Yamada, S. Kato, E. Iwata, S. Hayashida, Y. Kojima, M. Shinohara, I. Tojo, H. Nakahara, T. Yamaguchi, T. Kirita, H. Kurita, Y. Shibuya, S. Soutome, M. Akashi
Summary: Risk factors for denosumab-related osteonecrosis of the jaw after tooth extraction in cancer patients on oncologic doses of denosumab include pre-existing inflammation, corticosteroid therapy, periapical periodontitis, longer duration of denosumab therapy, and female sex. A short drug holiday did not protect against this complication.
OSTEOPOROSIS INTERNATIONAL
(2021)
Article
Multidisciplinary Sciences
Kota Morishita, Sakiko Soutome, Mitsunobu Otsuru, Saki Hayashida, Maho Murata, Miho Sasaki, Yukinori Takagi, Misa Sumi, Masahiro Umeda
Summary: The study found that a drug holiday of 3 months for medication-related osteonecrosis of the jaw in osteoporosis patients receiving antiresorptive agents does not promote sequestra separation or improve treatment outcomes, and early surgical therapy is recommended.
SCIENTIFIC REPORTS
(2022)
Article
Endocrinology & Metabolism
Judith Everts-Graber, Daniel Lehmann, John-Patrik Burkard, Benoit Schaller, Brigitta Gahl, HansJoerg Haeuselmann, Ueli Studer, Hans-Rudolf Ziswiler, Stephan Reichenbach, Thomas Lehmann
Summary: This study aimed to determine the risk of ONJ in a real-world population, showing a higher incidence rate in patients receiving denosumab therapy compared to those receiving BPs, with previous BP therapy potentially being an additional risk factor for ONJ development.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Review
Nutrition & Dietetics
Luca Dalle Carbonare, Monica Mottes, Maria Teresa Valenti
Summary: Osteonecrosis of the jaw is a severe clinical condition characterized by exposed bone that does not heal over time. Diagnosis is primarily clinical with imaging feedback playing a confirmatory role. Medication-related osteonecrosis of the jaw, particularly induced by bisphosphonates, has been widely discussed, but the exact mechanism remains debatable.
Review
Endocrinology & Metabolism
Athanasios D. Anastasilakis, Jessica Pepe, Nicola Napoli, Andrea Palermo, Christos Magopoulos, Aliya A. Khan, M. Carola Zillikens, Jean-Jacques Body
Summary: This study evaluates the differences of MRONJ among different patient categories and provides recommendations on how to mitigate the risk and optimally manage MRONJ. The results indicate that patients with advanced malignancies are at a higher risk for MRONJ compared to those with benign bone diseases, but the overall risk is considerably lower than the benefits of treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Oncology
Hiroaki Ikesue, Kohei Doi, Mayu Morimoto, Masaki Hirabatake, Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, Tohru Hashida
Summary: This study found that patients treated with denosumab for bone metastasis have a higher risk of developing medication-related osteonecrosis of the jaw (MRONJ) compared to those treated with zoledronic acid, highlighting the need for close monitoring for patients on denosumab.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Endocrinology & Metabolism
Guang Yang, Roy Williams, Lishu Wang, Nosha Farhadfar, Yiqing Chen, Alexander T. Loiacono, Jiang Bian, Lexie Shannon Holliday, Joseph Katz, Yan Gong
Summary: This study evaluated the incidence and risk factors for medication-related osteonecrosis of the jaw (MRONJ) related to bisphosphonates (BPs) or denosumab in cancer patients. The results showed that the rates of MRONJ associated with BPs and denosumab were similar, but patients receiving sequential treatment of these two drug classes had a much higher risk of MRONJ.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Oncology
Paola Bracchi, Ernesto Zecca, Cinzia Brunelli, Rosalba Miceli, Gabriele Tine, Massimo Maniezzo, Silvia Lo Dico, Mariangela Caputo, Morena Shkodra, Augusto T. T. Caraceni
Summary: This study aimed to assess the incidence of Medication Related Osteonecrosis of the Jaw (MRONJ) in cancer patients with bone metastases receiving Denosumab (Dmab) and identify potential risk factors. The results showed that middle-aged patients, dental treatments, and previous bisphosphonates administration were associated with a higher incidence of MRONJ.
Article
Environmental Sciences
Guillermo Pardo-Zamora, Yanet Martinez, Jose Antonio Moreno, Antonio J. Ortiz-Ruiz
Summary: MRONJ is a rare and severe disease with unclear exact cause and potential multifactorial origins. A case series of three stage 2 MRONJ patients showed complete healing within 12 months of therapeutic protocol application, with radiography demonstrating slow but progressive healing with normal bone structure. Conservative treatment and minimally invasive surgical intervention are effective for stage 2 MRONJ, while application of PRF-L in refractory cases can improve outcomes in soft tissue healing and bone regeneration, though further research is needed to confirm effectiveness.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Review
Endocrinology & Metabolism
Ha Young Kim
Summary: ARONJ is a rare but serious adverse event associated with bisphosphonate or denosumab administration, causing severe pain and deteriorated quality of life. Despite studies on its definition, epidemiology, pathophysiology, diagnosis, and treatment, the epidemiology and mechanisms of ARONJ have not been fully elucidated, emphasizing the importance of prevention and cooperation between physicians and dentists.
ENDOCRINOLOGY AND METABOLISM
(2021)
Article
Biotechnology & Applied Microbiology
Stephane Odet, Christophe Meyer, Camille Gaudet, Elise Weber, Julie Quenot, Stephane Derruau, Sebastien Laurence, Lisa Bompy, Marine Girodon, Brice Chatelain, Cedric Mauprivez, Esteban Brenet, Halima Kerdjoudj, Narcisse Zwetyenga, Philippe Marchetti, Anne-Sophie Hatzfeld, David Toubeau, Fabienne Pouthier, Xavier Lafarge, Heinz Redl, Mathilde Fenelon, Jean-Christophe Fricain, Roberta Di Pietro, Charlotte Ledouble, Thomas Gualdi, Anne-Laure Parmentier, Aurelien Louvrier, Florelle Gindraux
Summary: The use of human amniotic membrane (hAM) can promote tissue regeneration and healing in patients with medication-related osteonecrosis of the jaw (MRONJ). By using cryopreserved hAM, MRONJ can be effectively treated, leading to improved quality of life for patients.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Medicine, General & Internal
Zineb Assili, Gilles Dolivet, Julia Salleron, Claire Griffaton-Tallandier, Claire Egloff-Juras, Berengere Phulpin
Summary: This study evaluated the incidence of denosumab-related osteonecrosis of the jaw and found that the clinical extent of MRONJ was significantly less than their radiological extent. It is recommended to perform a CBCT during the diagnosis of MRONJ to explore the entire affected dental arch.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Cell Biology
Camille Gaudet, Stephane Odet, Christophe Meyer, Brice Chatelain, Elise Weber, Anne-Laure Parmentier, Stephane Derruau, Sebastien Laurence, Cedric Mauprivez, Esteban Brenet, Halima Kerdjoudj, Mathilde Fenelon, Jean-Christophe Fricain, Narcisse Zwetyenga, David Hoarau, Remi Curien, Eric Gerard, Aurelien Louvrier, Florelle Gindraux
Summary: Medication-related osteonecrosis of the jaw (MRONJ) is a complication caused by anti-resorptive agents and anti-angiogenesis drugs. We reviewed the literature and designed a questionnaire to collect information on clinical practices. However, we found missing data and a lack of consensus.